CompanyENTXNasdaqJerusalem

Entera Bio Ltd.

Entera Bio develops oral peptide and protein replacement therapies using its N-Tab® technology platform.

SEC EDGAR ClinicalTrials.gov enterabio.com

S-1Sep 11Latest SEC filing

Aug 18Latest story

August 2026

Entera Bio names Riccardo Camisasca as chief medical officer

Aug 18PeopleEntera Bio Ltd.

Entera Bio reports $274.99 million offering completed under Form D

Aug 12FinancingEntera Bio Ltd.

Entera Bio reports Q2 2026 results, cites FDA alignment on EB613 Phase 3 design

Aug 7Quarterly updateEntera Bio Ltd.

July 2026

Entera Bio raises $275 million in private placement led by BVF Partners funds

Jul 28PartnershipEntera Bio Ltd.

Entera Bio holds annual meeting, expands share pool and authorized shares

Jul 16PeopleEntera Bio Ltd.